GW Pharmaceuticals, PLC : American Depositary Shares Securities Litigation (2021)

Filing Deadline: July 26, 2021

If you purchased a significant amount of shares of GW Pharmaceuticals Plc American Depositary Shares (NASDAQ: GWPH), you have certain options. Investors should contact us before July 26, 2021.

 

Lawsuit Overview

Defendant:GW Pharmaceuticals Plc American Depositary Shares
Date Filed:May 27th, 2021
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:February 3rd, 2021
Class End Date:May 27th, 2021

On February 3, 2021, GW entered into an agreement and plan of merger pursuant to which the holders of GW ordinary shares would receive $16.66 in cash plus an amount of Jazz ordinary shares equal to an exchange ratio that would be calculated based upon Jazz’s share price, and holders of GW American Depositary Shares would receive approximately $200 per share in cash and $20 in Jazz stock in consideration for their shares (the “Merger Consideration”).

The Complaint alleges that on March 15, 2021, to convince GW shareholders to vote in favor of the Merger, Defendants caused a materially false and misleading Definitive Proxy Statement, subsequently amended and supplemented on April 14, 2021, to be filed with the SEC and disseminated to GW’s shareholders. The Complaint alleges that the Proxy was materially false and misleading with respect to GW’s financial projections and operations, the value of GW shareholders’ stock, and the fairness of the Merger Consideration.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for GW Pharmaceuticals Plc American Depositary Shares

 
First Identified Complaint

Kurt Ziegler, et al. v. GW Pharmaceuticals, PLC, et al.

Date Filed:May 27th, 2021
Class Period Start:February 3rd, 2021
Class Period End:May 27th, 2021
First Identified Complaint Filings
#Document TitleFiling Date